<p>拥有大量资金的投资者对 <strong>再生元制药</strong> (NASDAQ: REGN) 持乐观态度。</p>
<p>而散户交易者应该知道这一点。</p>
<p>我们今天注意到这一点，当交易出现在我们在 Benzinga 跟踪的公开可用期权历史中时。</p>
<p>无论这些是机构还是仅仅是富有的个人，我们都不知道。但当 REGN 发生如此重大的事情时，通常意味着有人知道即将发生什么。</p>
<p>那么我们如何知道这些投资者刚刚做了什么呢？</p>
<p>今天，Benzinga 的期权扫描仪发现了 11 笔不寻常的再生元制药期权交易。</p>
<p>这并不正常。</p>
<p>这些大资金交易者的整体情绪在 36% 看涨和 36% 看跌之间分裂。</p>
<p>在我们发现的所有特殊期权中，7 笔是看跌期权，总金额为 $344,526，4 笔是看涨期权，总金额为 $458,064。</p>
<h3>预测价格区间</h3>
<p>分析这些合约的成交量和未平仓合约，似乎大玩家在过去一个季度内关注再生元制药的价格区间为 $400.0 到 $800.0。</p>
<h3>成交量与未平仓合约发展</h3>
<p>评估成交量和未平仓合约是期权交易中的一个战略步骤。这些指标揭示了在指定行使价格下，投资者对再生元制药期权的流动性和兴趣。接下来的数据将可视化过去 30 天内与再生元制药重大交易相关的看涨和看跌期权的成交量和未平仓合约的波动，行使价格范围为 $400.0 到 $800.0。</p>
<h3>再生元制药期权活动分析：过去 30 天</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期权看涨图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png"/></p>
<h3>发现的最大期权：</h3>
<table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行使价格</strong></th>
<th><strong>总交易价格</strong></th>
<th align="right"><strong>未平仓合约</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$128.3</td>
<td>$122.4</td>
<td>$124.5</td>
<td>$630.00</td>
<td>$311.2K</td>
<td align="right">111</td>
<td align="right">25</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>扫描</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$775.00</td>
<td>$65.1K</td>
<td align="right">346</td>
<td align="right">42</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$12.3</td>
<td>$15.2</td>
<td>$775.00</td>
<td>$63.8K</td>
<td align="right">346</td>
<td align="right">122</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>扫描</td>
<td>看涨</td>
<td>01/16/26</td>
<td>$17.4</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$775.00</td>
<td>$61.5K</td>
<td align="right">346</td>
<td align="right">302</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>06/16/28</td>
<td>$185.0</td>
<td>$179.5</td>
<td>$185.0</td>
<td>$800.00</td>
<td>$55.5K</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
<h3>关于再生元制药</h3>
<p>再生元制药发现、开发和商业化用于治疗眼病、心血管疾病、癌症和炎症的产品。该公司有多个已上市产品，包括用于湿性年龄相关性黄斑变性和其他眼病的低剂量 Eylea 和 Eylea HD；在免疫学领域的 Dupixent；用于降低 LDL 胆固醇的 Praluent；在肿瘤学领域的 Libtayo；以及在类风湿关节炎领域的 Kevzara。再生元还与赛诺菲及其他合作伙伴独立开发单克隆抗体和双特异性抗体，并与早期阶段的合作伙伴关系引入新技术，包括 RNAi（Alnylam）和基于 Crispr 的基因编辑（Intellia）。</p>
<p>鉴于再生元制药最近的期权历史，现在适合关注该公司本身。我们旨在探讨其当前表现。</p>
<h3>再生元制药的当前市场状况</h3>
<ul>
<li>目前交易量为 269,395，REGN 的价格上涨 0.21%，现为 $760.5。</li>
<li>RSI 指标显示该股票目前在超买和超卖之间处于中性状态。</li>
<li>预计盈利发布将在 16 天内进行。</li>
</ul>
<h3>专家对再生元制药的看法</h3>
<p>在过去一个月中，2 位专家对该股票发布了评级，平均目标价格为 $840.0。</p>
<ul>
<li>一位来自美银证券的分析师将其评级提升至买入，设定新的目标价格为 $860。</li>
<li>一位来自 Truist Securities 的分析师决定维持对再生元制药的买入评级，目前目标价格为 $820。</li>
</ul>
<p>期权相比于仅交易股票是一种风险更高的资产，但它们具有更高的利润潜力。严肃的期权交易者通过每天学习、逐步进出交易、关注多个指标以及密切关注市场来管理这种风险。</p>

再生元制药

<p>投资者对再生元制药（NASDAQ:REGN）表现出乐观情绪，显著的期权交易表明潜在价格波动在 400 美元到 800 美元之间。最近的数据揭示交易者的情绪分歧，其中 36% 看涨，36% 看跌。该股票目前交易价格为 760.5 美元，上涨 0.21%，预计将在 16 天后发布财报。分析师们设定的目标价格平均为 840 美元，其中一位分析师将目标上调至 860 美元。期权交易风险较高，但对于认真投资者来说也提供了更大的盈利潜力</p>

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Regeneron Pharmaceuticals</strong> (NASDAQ: REGN).</p>
<div class="lb-trans"><p>拥有大量资金的投资者对 <strong>再生元制药</strong> (NASDAQ: REGN) 持乐观态度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者应该知道这一点。</p>
</div><p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我们今天注意到这一点，当交易出现在我们在 Benzinga 跟踪的公开可用期权历史中时。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>无论这些是机构还是仅仅是富有的个人，我们都不知道。但当 REGN 发生如此重大的事情时，通常意味着有人知道即将发生什么。</p>
</div><p>So how do we know what these investors just did?</p>
<div class="lb-trans"><p>那么我们如何知道这些投资者刚刚做了什么呢？</p>
</div><p>Today, Benzinga's options scanner spotted 11 uncommon options trades for Regeneron Pharmaceuticals.</p>
<div class="lb-trans"><p>今天，Benzinga 的期权扫描仪发现了 11 笔不寻常的再生元制药期权交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>这并不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 36% bullish and 36%, bearish.</p>
<div class="lb-trans"><p>这些大资金交易者的整体情绪在 36% 看涨和 36% 看跌之间分裂。</p>
</div><p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $344,526, and 4 are calls, for a total amount of $458,064.</p>
<div class="lb-trans"><p>在我们发现的所有特殊期权中，7 笔是看跌期权，总金额为 $344,526，4 笔是看涨期权，总金额为 $458,064。</p>
</div><h3>Predicted Price Range</h3>
<div class="lb-trans"><h3>预测价格区间</h3>
</div><p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $400.0 to $800.0 for Regeneron Pharmaceuticals during the past quarter.</p>
<div class="lb-trans"><p>分析这些合约的成交量和未平仓合约，似乎大玩家在过去一个季度内关注再生元制药的价格区间为 $400.0 到 $800.0。</p>
</div><h3>Volume &amp; Open Interest Development</h3>
<div class="lb-trans"><h3>成交量与未平仓合约发展</h3>
</div><p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Regeneron Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Regeneron Pharmaceuticals's substantial trades, within a strike price spectrum from $400.0 to $800.0 over the preceding 30 days.</p>
<div class="lb-trans"><p>评估成交量和未平仓合约是期权交易中的一个战略步骤。这些指标揭示了在指定行使价格下，投资者对再生元制药期权的流动性和兴趣。接下来的数据将可视化过去 30 天内与再生元制药重大交易相关的看涨和看跌期权的成交量和未平仓合约的波动，行使价格范围为 $400.0 到 $800.0。</p>
</div><h3>Regeneron Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<div class="lb-trans"><h3>再生元制药期权活动分析：过去 30 天</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2026/1768417244_0.png"/></p>
<h3>Biggest Options Spotted:</h3>
<div class="lb-trans"><h3>发现的最大期权：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$128.3</td>
<td>$122.4</td>
<td>$124.5</td>
<td>$630.00</td>
<td>$311.2K</td>
<td align="right">111</td>
<td align="right">25</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$775.00</td>
<td>$65.1K</td>
<td align="right">346</td>
<td align="right">42</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$12.3</td>
<td>$15.2</td>
<td>$775.00</td>
<td>$63.8K</td>
<td align="right">346</td>
<td align="right">122</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.4</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$775.00</td>
<td>$61.5K</td>
<td align="right">346</td>
<td align="right">302</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/16/28</td>
<td>$185.0</td>
<td>$179.5</td>
<td>$185.0</td>
<td>$800.00</td>
<td>$55.5K</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行使价格</strong></th>
<th><strong>总交易价格</strong></th>
<th align="right"><strong>未平仓合约</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$128.3</td>
<td>$122.4</td>
<td>$124.5</td>
<td>$630.00</td>
<td>$311.2K</td>
<td align="right">111</td>
<td align="right">25</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>扫描</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$775.00</td>
<td>$65.1K</td>
<td align="right">346</td>
<td align="right">42</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$12.3</td>
<td>$15.2</td>
<td>$775.00</td>
<td>$63.8K</td>
<td align="right">346</td>
<td align="right">122</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>扫描</td>
<td>看涨</td>
<td>01/16/26</td>
<td>$17.4</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$775.00</td>
<td>$61.5K</td>
<td align="right">346</td>
<td align="right">302</td>
</tr>
<tr>
<td>REGN</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>06/16/28</td>
<td>$185.0</td>
<td>$179.5</td>
<td>$185.0</td>
<td>$800.00</td>
<td>$55.5K</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
</div><h3>About Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>关于再生元制药</h3>
</div><p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<div class="lb-trans"><p>再生元制药发现、开发和商业化用于治疗眼病、心血管疾病、癌症和炎症的产品。该公司有多个已上市产品，包括用于湿性年龄相关性黄斑变性和其他眼病的低剂量 Eylea 和 Eylea HD；在免疫学领域的 Dupixent；用于降低 LDL 胆固醇的 Praluent；在肿瘤学领域的 Libtayo；以及在类风湿关节炎领域的 Kevzara。再生元还与赛诺菲及其他合作伙伴独立开发单克隆抗体和双特异性抗体，并与早期阶段的合作伙伴关系引入新技术，包括 RNAi（Alnylam）和基于 Crispr 的基因编辑（Intellia）。</p>
</div><p>In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<div class="lb-trans"><p>鉴于再生元制药最近的期权历史，现在适合关注该公司本身。我们旨在探讨其当前表现。</p>
</div><h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>再生元制药的当前市场状况</h3>
</div><ul>
<li>Currently trading with a volume of 269,395, the REGN's price is up by 0.21%, now at $760.5.</li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 16 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>目前交易量为 269,395，REGN 的价格上涨 0.21%，现为 $760.5。</li>
<li>RSI 指标显示该股票目前在超买和超卖之间处于中性状态。</li>
<li>预计盈利发布将在 16 天内进行。</li>
</ul>
</div><h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>专家对再生元制药的看法</h3>
</div><p>In the last month, 2 experts released ratings on this stock with an average target price of $840.0.</p>
<div class="lb-trans"><p>在过去一个月中，2 位专家对该股票发布了评级，平均目标价格为 $840.0。</p>
</div><ul>
<li>An analyst from B of A Securities has elevated its stance to Buy, setting a new price target at $860.</li>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $820.</li>
</ul>
<div class="lb-trans"><ul>
<li>一位来自美银证券的分析师将其评级提升至买入，设定新的目标价格为 $860。</li>
<li>一位来自 Truist Securities 的分析师决定维持对再生元制药的买入评级，目前目标价格为 $820。</li>
</ul>
</div><p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<div class="lb-trans"><p>期权相比于仅交易股票是一种风险更高的资产，但它们具有更高的利润潜力。严肃的期权交易者通过每天学习、逐步进出交易、关注多个指标以及密切关注市场来管理这种风险。</p>
</div>

这就是大户押注再生元制药的原因